News and Trends 17 Aug 2022 AUM LifeTech secures $400,000 grant for lung cancer immunotherapy program AUM LifeTech, Inc., a Philadelphia-based preclinical stage biotech company, has received a Small Business Innovation Research (SBIR) grant from the National Cancer Institute (NCI) of the National Institutes of Health (NIH) to advance its preclinical program in lung cancer immunotherapy using a non-viral RNA-targeting gene therapy approach. “This grant will help advance our preclinical immunotherapy […] August 17, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 17 Aug 2022 New partnership delivers clinically proven products and manufacturing processes for advanced therapies AGC Biologics has announced its partnership with supplier of human mesenchymal stem/stromal cells (hMSCs), RoosterBio Inc. The partnership, the companies say creates an end-to-end solution for the development and production of hMSCs and exosome therapeutics using RoosterBio’s well-established cell and media products and process development services together with AGC’s cell and gene therapy manufacturing capabilities. […] August 17, 2022 - 3 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 16 Aug 2022 Remedium raises more funds for osteoarthritis gene therapy candidate Remedium Bio, Inc., a biotech company developing novel gene therapies, has closed more than $2.3 million in its expanded seed round financing. Funding from the raise is being used to study Remedium’s lead product, a single-injection gene therapy potentially capable of reversing cartilage loss. The study is being undertaken in a collaboration with Tufts University […] August 16, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 8 Aug 2022 Allogenic immune cell therapies to be developed as three groups join forces Three entities have joined forces to develop allogenic immune cell therapies based on a platform that generates functionally mature immune cells from induced pluripotent stem cells (iPSCs). ElevateBio LLC is a technology-driven company focused on powering transformative cell and gene therapies. It announced recently (August 5) that it has formed a yet-to-be-named company co-founded by […] August 8, 2022 - 3 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 4 Aug 2022 RoslinCT and Lykan Bioscience combine to create cell therapy CDMO RoslinCT, a cell and gene therapy contract development and manufacturing organization (CDMO) developing life-changing therapies in Edinburgh’s BioQuarter, and Lykan Bioscience, a CDMO focused on cell-based therapies, have entered into a business combination agreement to form a global advanced therapies CDMO. The combined group will offer process development expertise and cGMP manufacturing for a range […] August 4, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 29 Jul 2022 Sarepta looks for quick approval for Duchenne muscular dystrophy gene therapy treatment U.S. company Sarepta Therapeutics, Inc. said it intends to submit a Biologics License Application (BLA) seeking accelerated approval for SRP-9001 (delandistrogene moxeparvovec) to treat ambulant individuals with Duchenne muscular dystrophy. SRP-9001 is an investigational gene therapy for Duchenne being developed in partnership with Roche. “We are delighted to confirm that based on the feedback we […] July 29, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 29 Jul 2022 Commercial personalized cancer cell profile developed in Taiwan Patients with stage 2 solid tumors could benefit from the world’s first commercial personalized cancer cell profiling, developed in Taiwan. Taipei-based CancerFree Biotech Ltd has developed the technology that will help stage 2 patients and above by shortening the selection process. The technology will be showcasing at US Bio 2022. This is the world’s first […] July 29, 2022 - 3 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 28 Jul 2022 AGC Biologics announces gene therapy partnership with Altheia Science A new development partnership between gene therapy company Altheia Sciences, which pioneers cell and gene treatments, and AGC Biologics, will look at strategies to treat autoimmune disease and cancer. Specifically, the partnership will help advance development of autoimmunity treatments, focused on modulating PD-L1 expression in patients’ hematopoietic stem and progenitor cells, into clinical testing. PD-L1 […] July 28, 2022 - 2 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 27 Jul 2022 SomaLogic acquires DNA nanotechnology company Palamedrix Colorado-based AI data-driven proteomics technology company SomaLogic has entered into an agreement to acquire Palamedrix, Inc., which is involved in DNA nanotechnology. Palamedrix provides scientific and engineering expertise and miniaturization technology, which SomaLogic intends to leverage as it develops the next generation of the SomaScan assay. Proteomic tool The SomaScan assay is a multiplexed, sensitive, quantitative, […] July 27, 2022 - 3 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 26 Jul 2022 Oxford Biomedica sets up new project and signs LSA Oxford Biomedica plc, a UK-based gene and cell therapy group, has initiated a new project with Orchard Therapeutics utilizing the company’s LentiStable technology. The group also announced the signing of a new licence and supply agreement (LSA) with an undisclosed US-based private biotech company advancing a new generation of adoptive cell therapies. LentiStable technology As […] July 26, 2022 - 4 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 20 Jul 2022 Upstaza gets nod from Europe for AADC deficiency treatment PTC Therapeutics, Inc. says Upstaza (eladocagene exuparvovec) has been given marketing authorization by the European Commission. Upstaza is the first approved disease-modifying treatment for aromatic L-amino acid decarboxylase (AADC) deficiency, and the first marketed gene therapy directly infused into the brain. It is approved for patients 18 months and older. “Today’s approval from the European […] July 20, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
More News! 18 Jul 2022 Purespring Therapeutics and SwanBio Therapeutics announce agreement for use of FunSel screening platform A licensing agreement for use of the FunSel screening platform has been announced by Purespring Therapeutics and SwanBio. Under the terms of the agreement, SwanBio will license the FunSel screening platform from Purespring to explore new targets for early-stage pipeline programs. SwanBio will have the option to develop any targets identified and to own and […] July 18, 2022 - 2 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email